HK1192546A1 - 哌啶- -基氧基 -異喹啉- -酮鹽酸鹽的結晶性溶劑化物 - Google Patents

哌啶- -基氧基 -異喹啉- -酮鹽酸鹽的結晶性溶劑化物

Info

Publication number
HK1192546A1
HK1192546A1 HK14105721.9A HK14105721A HK1192546A1 HK 1192546 A1 HK1192546 A1 HK 1192546A1 HK 14105721 A HK14105721 A HK 14105721A HK 1192546 A1 HK1192546 A1 HK 1192546A1
Authority
HK
Hong Kong
Prior art keywords
isoquinolin
yloxy
piperidin
hydrochloride
crystalline solvates
Prior art date
Application number
HK14105721.9A
Other languages
English (en)
Inventor
Norbert Nagel
Bruno Baumgartner
Harald Berchtold
Oliver Plettenburg
Dieter Kadereit
Mandy Mohnicke
Simon Gessler
Joachim Tillner
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of HK1192546A1 publication Critical patent/HK1192546A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pregnancy & Childbirth (AREA)
HK14105721.9A 2011-07-08 2014-06-17 哌啶- -基氧基 -異喹啉- -酮鹽酸鹽的結晶性溶劑化物 HK1192546A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11305890 2011-07-08
EP11306033 2011-12-29
PCT/EP2012/062431 WO2013007518A1 (en) 2011-07-08 2012-06-27 Crystalline solvates of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride

Publications (1)

Publication Number Publication Date
HK1192546A1 true HK1192546A1 (zh) 2014-08-22

Family

ID=46397257

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14105721.9A HK1192546A1 (zh) 2011-07-08 2014-06-17 哌啶- -基氧基 -異喹啉- -酮鹽酸鹽的結晶性溶劑化物

Country Status (22)

Country Link
US (2) US8710078B2 (zh)
EP (1) EP2729460B1 (zh)
JP (1) JP6357100B2 (zh)
KR (1) KR102013566B1 (zh)
CN (1) CN103781778B (zh)
AU (1) AU2012283276B2 (zh)
CA (1) CA2843773C (zh)
CO (1) CO6870040A2 (zh)
CY (1) CY1118326T1 (zh)
DK (1) DK2729460T3 (zh)
ES (1) ES2568245T3 (zh)
HK (1) HK1192546A1 (zh)
HR (1) HRP20160356T1 (zh)
HU (1) HUE027309T2 (zh)
IN (1) IN2014CN00817A (zh)
MA (1) MA35340B1 (zh)
PL (1) PL2729460T3 (zh)
RU (1) RU2619129C2 (zh)
SG (1) SG2014007520A (zh)
SI (1) SI2729460T1 (zh)
WO (1) WO2013007518A1 (zh)
ZA (1) ZA201400941B (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6357100B2 (ja) * 2011-07-08 2018-07-11 サノフイ ６−（ピペリジン−４−イルオキシ）−２ｈ−イソキノリン−１−オン塩酸塩の結晶性溶媒和物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2396079A1 (en) * 2000-01-07 2001-07-19 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
CA2615577C (en) 2005-07-26 2014-09-09 Sanofi-Aventis Piperidinyl-substituted isoquinolone derivatives as rho-kinase inhibitors
TW200738682A (en) 2005-12-08 2007-10-16 Organon Nv Isoquinoline derivatives
WO2007101242A1 (en) 2006-02-28 2007-09-07 Meadwestvaco Packaging Systems Llc Carton for tapered and cylindrical articles and blank therefor
ES2363105T3 (es) * 2006-12-27 2011-07-20 Sanofi-Aventis Isoquinolinas sustituidas y su uso como inhibidores de rho-quinasa.
AU2007338406B2 (en) * 2006-12-27 2012-08-09 Sanofi-Aventis Substituted isoquinoline and isoquinolinone derivatives as inhibitors of Rho-kinase
WO2009080335A1 (en) * 2007-12-26 2009-07-02 Sanofi-Aventis Process for the preparation of 6-substituted-1-(2h)-isoquinolinones
JP6357100B2 (ja) * 2011-07-08 2018-07-11 サノフイ ６−（ピペリジン−４−イルオキシ）−２ｈ−イソキノリン−１−オン塩酸塩の結晶性溶媒和物

Also Published As

Publication number Publication date
JP2014518235A (ja) 2014-07-28
HUE027309T2 (en) 2016-10-28
RU2014104358A (ru) 2015-08-20
JP6357100B2 (ja) 2018-07-11
US8710078B2 (en) 2014-04-29
RU2619129C2 (ru) 2017-05-12
EP2729460B1 (en) 2016-01-13
EP2729460A1 (en) 2014-05-14
CA2843773C (en) 2018-11-06
CA2843773A1 (en) 2013-01-17
US20130012444A1 (en) 2013-01-10
HRP20160356T1 (hr) 2016-05-06
ES2568245T3 (es) 2016-04-28
MA35340B1 (fr) 2014-08-01
SG2014007520A (en) 2014-07-30
AU2012283276A1 (en) 2014-02-27
CN103781778A (zh) 2014-05-07
CY1118326T1 (el) 2017-06-28
AU2012283276B2 (en) 2014-07-24
WO2013007518A1 (en) 2013-01-17
CN103781778B (zh) 2015-10-07
US20140221656A1 (en) 2014-08-07
KR102013566B1 (ko) 2019-08-23
SI2729460T1 (sl) 2016-05-31
IN2014CN00817A (zh) 2015-04-03
NZ620864A (en) 2015-08-28
CO6870040A2 (es) 2014-02-20
PL2729460T3 (pl) 2016-07-29
KR20140045550A (ko) 2014-04-16
DK2729460T3 (en) 2016-04-18
ZA201400941B (en) 2015-05-27

Similar Documents

Publication Publication Date Title
HK1192247A1 (zh) 作為激酶抑制劑的雜環化合物
HK1222647A1 (zh) 激酶抑制劑
HK1199728A1 (zh) 種新的普利多匹定鹽酸鹽多晶型形態
HK1203487A1 (zh) 晶體 激酶抑制劑
EP2680697A4 (en) PROCESS FOR PREPARING AN OREXINE RECEPTOR ANTAGONIST
HUE048834T2 (hu) Kináz inhibitorok
IL229028A0 (en) Kinase inhibitors
HK1199873A1 (zh) 激酶抑制劑
EP2758387A4 (en) Pyridine compounds as kinase inhibitors
ZA201207397B (en) Process for the preparation of dexlansoprazole
HK1207081A1 (zh) 二氫嘧啶衍生物的晶型
EP2663306A4 (en) POLYMORPHS OF DEXLANSOPRAZOLE SALTS
HK1192546A1 (zh) 哌啶- -基氧基 -異喹啉- -酮鹽酸鹽的結晶性溶劑化物
HK1192234A1 (zh) 哌啶- -基氧基 -異喹啉- -酮鹽酸鹽的多晶型物
EP2872489A4 (en) SYNTHESIS OF ACRIDINIUM COMPOUNDS BY N-ALKYLATION OF ACRIDONES
ZA201309732B (en) Process for the preparation of dexlansoprazole